Merck and Moderna Announce Positive Phase 3 Results for Intismeran Autogene Plus Pembrolizumab in High-Risk Melanoma - The Babak Lab

The Babak Lab shared on LinkedIn: 'Merck and Moderna have announced positive top-line results from the Phase 3 INTerpath-001 trial of intismeran autogene (V940) + pembrolizumab in patients with resected high-risk melanoma. Key Results INTerpath-001 is the first positive Phase 3 trial of an individualized neoantigen therapy. Disclaimer: These are top-line results from an official Merck and Moderna press release. Full INTerpath-001 results are awaiting peer review and publication. Image generated using Sora by OpenAI. Merck and Moderna Announce Phase 3 INTerpath-001 Trial of Intismeran Autogene Plus KEYTRUDA® Met Endpoints of Recurrence-Free Survival (RFS) and Distant Metastasis-Free Survival (DMFS) in Patients With Completely Resected Stage IIB-IV Melanoma.' Other articles about melanoma on Oncodaily.